ClinicalTrials.gg
Not yet recruitingNCT07796698IC-PEEPUpdated Sep 1, 2026

Effect of PEEP on Indirect Calorimetry in Critically Ill Patients

An interventional study of Protocolized PEEP Adjustment in Indirect Calorimetry, Mechanical Ventilation and Positive End-Expiratory Pressure, sponsored by Vastra Gotaland Region. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Vastra Gotaland Region · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Indirect calorimetry is used in intensive care to measure how much oxygen a patient consumes and how much carbon dioxide is produced. These measurements are used to estimate energy expenditure and help guide nutritional treatment. In mechanically ventilated patients, however, ventilator settings may potentially influence the accuracy of indirect calorimetry.

This study will investigate whether changes in positive end-expiratory pressure (PEEP), a routinely used ventilator setting, affect measurements obtained by indirect calorimetry in critically ill mechanically ventilated adults.

Each participant will undergo indirect calorimetry at three PEEP levels: 8, 12, and 16 cmH2O. Each PEEP level will be maintained for a stabilization period before measurements are obtained. Other ventilator settings will be kept unchanged during the measurement sequence whenever clinically feasible.

The study will compare oxygen consumption (VO2), carbon dioxide production (VCO2), respiratory quotient (RQ), and resting energy expenditure (REE) across the three PEEP levels. The aim is to determine whether clinically relevant changes in PEEP systematically influence indirect calorimetry measurements and their interpretation.

Read the detailed description

Indirect calorimetry (IC) is considered a reference method for assessment of energy expenditure in critically ill patients. It measures oxygen consumption (VO2) and carbon dioxide production (VCO2), from which respiratory quotient (RQ) and resting energy expenditure (REE) are calculated. Reliable measurements are important when IC is used to guide nutritional therapy in mechanically ventilated intensive care patients.

Measurement accuracy may potentially be influenced by ventilator settings and changes in respiratory mechanics. Positive end-expiratory pressure (PEEP) is frequently adjusted during intensive care, but there is limited clinical evidence regarding whether changes in PEEP within commonly used ranges systematically affect contemporary indirect calorimetry measurements. The approved research project therefore includes a physiological substudy specifically examining the influence of PEEP on VO2, VCO2, RQ, and REE.

This is a prospective, single-center, repeated-measures physiological study conducted in mechanically ventilated adult intensive care patients at Sahlgrenska University Hospital. Participants undergo indirect calorimetry during a standardized sequence of three PEEP levels: 8, 12, and 16 cmH2O. Each participant therefore serves as their own control.

At each PEEP level, the patient is allowed to reach a stable condition before indirect calorimetry measurements are obtained. The ethics protocol specifies a stabilization period before measurement and that other ventilator settings should remain unchanged during the PEEP sequence. The final operational study protocol uses PEEP levels of 8, 12, and 16 cmH2O.

Indirect calorimetry measurements will include VO2, VCO2, RQ, and REE. Measurements will be performed under standardized conditions, with attention to measurement stability and ventilator leakage. In the underlying research protocol, acceptable IC measurement periods are defined using steady-state criteria and controlled ventilator conditions.

The primary objective is to determine whether VO2, VCO2, RQ, and REE change systematically across PEEP levels of 8, 12, and 16 cmH2O. Repeated measurements will be analyzed using mixed-effects models accounting for clustering of observations within participants.

PEEP changes are performed within clinically accepted ranges under continuous intensive care monitoring. The measurement sequence will be interrupted if clinically relevant deterioration in hemodynamics, oxygenation, or other physiological parameters occurs. The ethics protocol specifically requires PEEP changes to remain within clinically acceptable levels and to be discontinued if adverse physiological effects are observed.

A relative difference of 10% in indirect calorimetry-derived measurements between PEEP levels was considered clinically meaningful. Assuming a within-participant standard deviation of approximately 12.5%, corresponding to a standardized paired effect size of 0.8, approximately 15 evaluable participants are required to achieve 80% power at a two-sided alpha level of 0.05. To account for incomplete measurement sequences and technically inadequate indirect calorimetry measurements, 20 participants are planned for enrollment.

02

Conditions studied

  • Indirect Calorimetry
  • Mechanical Ventilation
  • Positive End-Expiratory Pressure

Browse trials for

Keywords

  • Indirect calorimetry
  • PEEP
  • Positive end-expiratory pressure
  • Critical illness
  • Intensive care
  • Oxygen consumption
  • VO2
  • Carbon dioxide production
  • VCO2
  • Respiratory quotient
  • RQ
  • Resting energy expenditure
  • REE
03

In context

Critical Illness

1,780 studies on the registry are indexed under Critical Illness; 442 are open to participants now.

This study's planned enrollment of 20 is below the median of 90 across 926 interventional studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

Vastra Gotaland Region is the lead sponsor of 276 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Admitted to CIVA or NIVA at Sahlgrenska University Hospital.
  • Receiving invasive mechanical ventilation.
  • Expected intensive care stay longer than 72 hours.
  • Arterial catheter in place.
  • Clinical condition considered sufficiently stable by the responsible physician and research nurse to undergo the study-specific PEEP sequence.
  • PEEP levels of 8, 12, and 16 cmH2O considered clinically acceptable for the participant during the study measurement period.

Exclusion criteria

Exclusion Criteria:

  • Ongoing or planned continuous renal replacement therapy or intermittent hemodialysis (CRRT/iHD).
  • Extracorporeal membrane oxygenation (ECMO).
  • Fraction of inspired oxygen (FiO2) >0.70.
  • Severe renal failure or rapidly increasing creatinine where metabolic measurements may be difficult to interpret.
  • Terminal illness or decision for end-of-life care.
  • Previous participation in the study during the same ICU admission.
  • Clinical instability or other condition judged by the responsible physician to make the PEEP measurement sequence unsafe or inappropriate.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Sequential PEEP Levels

    All participants undergo indirect calorimetry measurements during a standardized sequence of PEEP levels at 8, 12, and 16 cmH2O. Each PEEP level is maintained for a predefined stabilization period before measurement. Other ventilator settings are kept unchanged whenever clinically feasible. Each participant therefore serves as their own control.

    Other: Protocolized PEEP Adjustment

Interventions

  • OtherProtocolized PEEP Adjustment

    Positive end-expiratory pressure (PEEP) is adjusted sequentially to 8, 12, and 16 cmH2O during a single study session. Each level is maintained until the predefined stabilization criteria are met before indirect calorimetry measurements are obtained. The sequence is performed under continuous intensive care monitoring and is discontinued if clinically relevant deterioration occurs.

06

What researchers measure

Primary outcomes

  1. Resting Energy Expenditure Across PEEP Levels

    Resting energy expenditure (REE), measured by indirect calorimetry and expressed in kcal/day, will be compared within participants across PEEP levels of 8, 12, and 16 cmH2O. The primary objective is to determine whether changes in PEEP produce systematic and clinically meaningful changes in measured REE.

    Time frame: During a single study session: after approximately 20 minutes at each PEEP level (8, 12, and 16 cmH2O)

Secondary outcomes

  1. Oxygen Consumption Across PEEP Levels

    VO₂ in mL/min compared within participants at PEEP 8, 12, and 16 cmH₂O.

    Time frame: During a single study session: after approximately 20 minutes at each PEEP level (8, 12, and 16 cmH2O)

  2. Carbon Dioxide Production Across PEEP Levels

    VCO₂ in mL/min compared within participants at the three PEEP levels.

    Time frame: During a single study session: after approximately 20 minutes at each PEEP level (8, 12, and 16 cmH2O)

  3. Respiratory Quotient Across PEEP Levels

    RQ calculated as VCO₂/VO₂ and compared within participants at the three PEEP levels.

    Time frame: During a single study session: after approximately 20 minutes at each PEEP level (8, 12, and 16 cmH2O)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — The feasibility and conditions for sharing de-identified individual participant data have not yet been determined. Any future data sharing will be subject to applicable ethical approvals, data protection regulations, institutional policies, and appropriate data-sharing agreements.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2028, 19 months later.

Of 399 non-industry interventional studies with no phase under Critical Illness, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 19 months is close to that.

Counting every sponsor, half of 403 studies reached it within 21 months; a quarter within 12 and three quarters within 40.

Critical Illness covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2026
First posted
Sep 1, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Jun 1, 2028
CompletionEst.
Oct 1, 2028
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07796698
Responsible party
Carl Sjödin (Principal Investigator and Doctoral Student, Vastra Gotaland Region) — Principal investigator
First posted
Sep 1, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jun 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Sep 1, 2026

Study contacts

Carl Sjödin, PhD student
Contact
carl.sjodin@vgregion.se
0707163277

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion